# Bio‐Assisted Synthesis of Reduced Graphene Oxide Nanosheets From Graphene Oxide: Promising and Efficient Cytotoxic and Antidiabetic Potency in In Vitro, Kinetic, and In Silico Models

**Authors:** Mansi Yadav, Divya Vashishth, Monika Bhardwaj, Jaya Parkash Yadav, Sudhir Kumar Kataria

PMC · DOI: 10.1155/ijbm/5521416 · International Journal of Biomaterials · 2026-02-17

## TL;DR

This paper explores using plant-based methods to create graphene nanosheets with potential uses in fighting cancer and diabetes.

## Contribution

A novel antidiabetic agent derived from C. igneus leaf-based reduced graphene oxide nanosheets is proposed.

## Key findings

- C. igneus leaf extract successfully synthesizes stable reduced graphene oxide nanosheets.
- The nanosheets show significant cytotoxic effects on liver and U87MG cells and enhance glucose uptake.
- Molecular docking and simulations confirm corosolic acid's stability in enzyme inhibition.

## Abstract

Green chemistry has recently made strides in the sustainable synthesis of next‐generation nanomaterials using reducing agents sourced from plants. Biocompatible conversion of reduced graphene oxide from graphene oxide nanomaterials is of particular interest in medical applications. The leaf extract of C. igneus functions as a reducing agent to produce reduced graphene oxide nanosheets from its precursor graphene oxide. A variety of characterization techniques were employed to confirm the formation and stability of reduced graphene oxide nanosheets. The cytotoxicity and glucose uptake potential of nanosheets have been evaluated through in vitro cell‐based assays. The MTT assay revealed a concentration‐dependent cytotoxic effect on Chang liver and U87MG cells, with maximum 84.5% and 76.3% cell viability, respectively. Reduced graphene oxide exhibited a significant rise in glucose uptake, comparable to the metformin drug, with increasing concentration. Enhanced glucose transport mediated by the nanosheets resulted in increased glucose uptake. Effective IC50 values of 84.46 μg·mL−1 and 93.83 μg·mL−1 were obtained in vitro enzyme inhibition studies against α‐amylase and α‐glucosidase, respectively. The enzyme kinetic investigation found noncompetitive inhibition for both enzymes. Molecular docking studies of C. igneus leaf derivatives were performed against α‐amylase and α‐glucosidase. Corosolic acid was selected based on favorable docking scores, binding interactions, and low root‐mean‐square deviation and was subjected to molecular dynamics simulations, which confirmed the stability of the resulting complex. This study concludes that reduced graphene oxide nanosheets derived from C. igneus leaves represent a novel antidiabetic agent that can reduce blood glucose levels and mitigate the complications associated with Type II diabetes.

## Linked entities

- **Chemicals:** corosolic acid (PubChem CID 6918774), metformin (PubChem CID 4091)
- **Diseases:** Type II diabetes (MONDO:0005148)

## Full-text entities

- **Genes:** AMY2A (amylase alpha 2A) [NCBI Gene 279] {aka AMY2, PA}, ABCB1 (ATP binding cassette subfamily B member 1) [NCBI Gene 5243] {aka ABC20, CD243, CLCS, ENPAT, GP170, MDR1}, CYP3A4 (cytochrome P450 family 3 subfamily A member 4) [NCBI Gene 1576] {aka CP33, CP34, CYP3A, CYP3A3, CYPIIIA3, CYPIIIA4}, CYP2C9 (cytochrome P450 family 2 subfamily C member 9) [NCBI Gene 1559] {aka CPC9, CYP2C, CYP2C10, CYPIIC9, P450-2C9, P450IIC9}, SLC2A4 (solute carrier family 2 member 4) [NCBI Gene 6517] {aka GLUT4}, CYP1A2 (cytochrome P450 family 1 subfamily A member 2) [NCBI Gene 1544] {aka CP12, CYPIA2, P3-450, P450(PA)}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, PGP (phosphoglycolate phosphatase) [NCBI Gene 283871] {aka AUM, G3PP, PGPase}, INSR (insulin receptor) [NCBI Gene 3643] {aka CD220, HHF5}, CYP2C19 (cytochrome P450 family 2 subfamily C member 19) [NCBI Gene 1557] {aka CPCJ, CYP2C, CYPIIC17, CYPIIC19, P450C2C, P450IIC19}, GCG (glucagon) [NCBI Gene 2641] {aka GLP-1, GLP1, GLP2, GRPP}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, SI (sucrase-isomaltase) [NCBI Gene 6476], CYP4F3 (cytochrome P450 family 4 subfamily F member 3) [NCBI Gene 4051] {aka CPF3, CYP4F, CYPIVF3, LTB4H}, CYP2D6 (cytochrome P450 family 2 subfamily D member 6 (gene/pseudogene)) [NCBI Gene 1565] {aka CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2}
- **Diseases:** ADMET (MESH:C562790), glioblastoma (MESH:D005909), abdominal discomfort (MESH:D000007), T2DM (MESH:D003924), Cytotoxicity (MESH:D064420), ADME/T (MESH:D001260), carcinogenic (MESH:D011230), diabetes complications (MESH:D048909), diarrhea (MESH:D003967), flatulence (MESH:D005414), cancer (MESH:D009369), diabetes (MESH:D003920), GO (MESH:D028361), Hyperglycemia (MESH:D006943), glioma (MESH:D005910), inflammatory (MESH:D007249)
- **Chemicals:** ROS (MESH:D017382), saponin (MESH:D012503), glycosides (MESH:D006027), H2SO4 (MESH:C033158), voglibose (MESH:C102817), DMSO (MESH:D004121), flavonoid (MESH:D005419), Glucose (MESH:D005947), Epoxide (MESH:D004852), hydrogen (MESH:D006859), alcohol (MESH:D000438), Oleic acid (MESH:D019301), PBS (MESH:D007854), LYS (MESH:D008239), Na2CO3 (MESH:C005686), sucrose (MESH:D013395), L-glutamine (MESH:D005973), CO2 (MESH:D002245), polyphenols (MESH:D059808), carbohydrate (MESH:D002241), KMnO4 (MESH:D011196), Tannins (MESH:D013634), phenols (MESH:D010636), starch (MESH:D013213), amino acid (MESH:D000596), MTT (MESH:C070243), Thiol (MESH:D013438), phenyl hydrazine (MESH:C030299), ASP (MESH:D001224), penicillin (MESH:D010406), oligosaccharides (MESH:D009844), doxorubicin (MESH:D004317), 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MESH:C022616), maltose (MESH:D008320), K3[Fe(CN)6 (MESH:C028033), Corosolic Acid (MESH:C113861), H2O2 (MESH:D006861), Graphene (MESH:D006108), Acarbose (MESH:D020909), Aq-CI (-), Diosgenin (MESH:D004144), hyaluronic acid (MESH:D006820), sodium hydroxide (MESH:D012972), hydroxyl (MESH:D017665), blood glucose (MESH:D001786), asparagine (MESH:D001216), ethanol (MESH:D000431), glutamic acid (MESH:D018698), alkaloids (MESH:D000470), vitamin C (MESH:D001205), terpenoids (MESH:D013729), Cianidanol (MESH:D002392), disaccharides (MESH:D004187), NaNO3 (MESH:C031618), metformin (MESH:D008687), imidazole (MESH:C029899), TYR (MESH:D014443), phenol (MESH:D019800), water (MESH:D014867), Pd (MESH:D010165)
- **Species:** Chamaecostus cuspidatus (species) [taxon 168191], Homo sapiens (human, species) [taxon 9606], Daucus carota (carrot, species) [taxon 4039], Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932]
- **Cell lines:** U87 glioblastoma — Homo sapiens (Human), Glioblastoma, Cancer cell line (CVCL_0022), 4J5T — Canis lupus familiaris (Dog), Canine glioma, Cancer cell line (CVCL_W822), HepG2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027), Chang — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0238)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12911526/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12911526/full.md

## References

76 references — full list in the complete paper: https://tomesphere.com/paper/PMC12911526/full.md

---
Source: https://tomesphere.com/paper/PMC12911526